Immunotherapy News and Research

Latest Immunotherapy News and Research

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Asterias Biotherapeutics, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.

17 Feb 2016

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) is hosting its second Annual New Treatments in Oncology (ANTO) conference, focused on advances in cancer research, new treatments and patient care.

17 Feb 2016

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

The quest to bring immunotherapy into widespread clinical use against cancer and infectious diseases has made great strides in recent years.

15 Feb 2016

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.

12 Feb 2016

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences.

10 Feb 2016

Study provides new insights into breast cancer metastasis

It has long been thought that cancer metastasizes, or spreads, when a single cancer cell escapes from the original tumor, travels through the bloodstream and sets up shop in distant organs. However, a growing body of evidence suggests that these bad actors don't travel alone; instead they migrate through the body in cellular clusters, like gangs.

2 Feb 2016

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

A team of Georgia State University researchers is fighting cancers using a combination of therapies and recently found ways that radiation could maximize responses to novel immune-based therapeutic approaches to fight cancer.

1 Feb 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia.

29 Jan 2016

Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Severe enterovirus 71 neurological disease in children predominantly involves the spinal cord and brainstem and can be quickly recognised using the World Health Organisation classification of clinicoradiological syndromes, study findings suggest.

29 Jan 2016

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S.

29 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company.

From Quest Diagnostics 27 Jan 2016

Sensitive computational method could help reveal effect of the immune system on cancer

A study by researchers at Norris Cotton Cancer Center has shown that a very sensitive computational method can be used to reveal the human immune system's effect on cancer. The Dartmouth study was the first to perform an in-depth computational examination of how immune activity translates to prognosis in breast cancer.

22 Jan 2016

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals.

22 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

20 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Immunotherapy News and Research

Latest Immunotherapy News and Research

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

Study provides new insights into breast cancer metastasis

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

Overall EU cancer, leukaemia mortality rates to fall in 2016

Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Sensitive computational method could help reveal effect of the immune system on cancer

Researchers explore ways to use light to combat cancer

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Immunotherapy could be the future of cancer treatments

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

PD-L1 inhibition well-tolerated, active in metastatic RCC

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Immunotherapy News and Research

Latest Immunotherapy News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in